Viewpoint: vaccine inequity in the spotlight. by Bittaye, Mustapha et al.
  1Bittaye M, et al. Arch Dis Child Month 2021 Vol 0 No 0
Viewpoint
Viewpoint: vaccine inequity in 
the spotlight
Mustapha Bittaye,1 Effua Usuf,2 Ed Clarke   3
Vaccine inequity has never before been in 
the public eye as it has been in the last 
months. The profound inequities in 
COVID- 19 vaccine supply which have 
been allowed to develop, driven largely 
by perceived national self- interest, 
reached the world stage at the G7 
meeting in June. Despite this, less than 
2% of the population of many low- 
income African countries have been 
vaccinated against COVID- 19, while 
more than half of those living in most 
high- income settings have received at 
least one, and in many case two vaccine 
doses. An increasing number of countries 
are now vaccinating children from the 
age of 12, despite risk–benefit analysis 
being less certain, and are stock- piling 
vaccines for booster immunisations, in 
the absence of indication that these will 
be required on widespread basis. Both 
approaches are in direct conflict with the 
current position of the WHO.
The primary arguments that have 
been put forward to address these ineq-
uities have focused on self- protection 
(‘Nobody is safe until everybody is 
safe’) and on ensuring global economic 
recovery. An expectation that counties 
will donate ‘surplus’ vaccines has also 
largely replaced the premise of vaccine 
equity. Although it may be that only argu-
ments appealing ultimately to national 
self- interest have the necessary traction, 
they are largely specific to pandemic 
COVID- 19 vaccination, thus do not put 
the current inequalities in their wider 
context. Such context is essential, given 
the ultimate aim must surely be to mini-
mise all excess vaccine- preventable 
deaths due to the pandemic, rather than 
solely those deaths directly attributable 
to SARS- CoV- 2 infection.
Modelling studies and WHO policy 
recommendations have supported 
sustaining routine childhood immu-
nisation throughout the pandemic.1 2 
However, vaccine programmes in many 
countries in sub- Saharan Africa are 
fragile; having limited capacity to cover 
for either delays in vaccine supply, or 
for having additional demands placed 
on staff and resources—both of which 
have occurred to an unprecedented 
level during the current pandemic. Mass 
vaccination campaigns, including for 
measles and polio, which are essential 
to maintaining population immunity and 
to outbreak response, have also been 
delayed. In addition, reductions in vacci-
nation coverage for such programmatic 
reasons are being multiplied by misin-
formation and rumours circulating, for 
example, suggesting COVID- 19 vaccines 
are being deployed in Africa for the 
purpose of population control.3 From 
our own experience in The Gambia, such 
rumours are having a negative impact on 
vaccine confidence overall and hence on 
the uptake of other vaccines.
Given these factors, progress 
addressing the pre- existing inequi-
ties in the availability of life- saving 
vaccines across sub- Saharan African, 
as set out last year in the Immuniza-
tion Agenda 2030—itself a roadmap 
to ‘leave no one behind’4—will be 
reversed if not considered in tandem 
with efforts to address the current 
inequity in COVID- 19 vaccine supply. 
Hundreds of thousands of under 5 years 
old continue to die annually from 
vaccine- preventable pneumococcal 
and Haemophilus influenzae type b 
disease, and from rotavirus diarrhoea. 
The number of preventable deaths from 
measles increased to beyond 200 000 
again globally in 2019 and any transient 
reduction in cases reported during the 
pandemic due to reduced population 
movement and social mixing, combined 
with compromised surveillance, are 
expected to rebound. Polio eradication 
is also at a critical juncture as cases of 
vaccine- derived poliovirus increase 
rapidly, particularly in West Africa. The 
2022–2026 Polio Eradication Strategy, 
launched in June this year, emphasises 
the critical need to address polio vacci-
nation, not in isolation, but as part of 
the wider vaccination programme and 
may thus be considered as a benchmark 
for future COVID- 19 vaccination.5 
Existing inequities in the availability of 
human papillomavirus (HPV) vaccines 
mean that, without action, women will 
continue to die from cervical cancer 
in Africa for decades to come, while 
high- income settings reach elimina-
tion goals. These and other inequities 
disproportionately impact on the health 
and well- being of children and women. 
Therefore, addressing them is also vital 
if key Sustainable Development Goal 
targets are to be met.
The current sporadic and unpre-
dictable delivery of short shelf- life 
COVID- 19 vaccines, particularly from 
different manufacturers, through the 
COVAX facility and other mecha-
nisms, will continue to make it logisti-
cally difficult to attain high coverage, 
even in frontline healthcare workers 
and other priority groups. It is also 
the most sure- fire way of maximising 
ongoing disruption to other vaccina-
tion programmes and of driving public 
mistrust and reduce vaccine confidence 
overall. WHO figures indicate that 
global diphtheria, tetanus and pertussis 
vaccine coverage in infancy fell by 3%, 
to 83% in 2020. The number of ‘zero- 
dose’, completely unvaccinated children 
increased by nearly 3.5 million, while 
the number of girls who were incom-
pletely vaccinated against HPV rose by 
1.6 million.6 There is currently a very 
real danger that a profound and long- 
lasting legacy of the current pandemic 
will be in the lives of children and 
women lost now, and in the future, due 
to other vaccine- preventable diseases.
Achieving nominal, although delayed, 
equity in COVID- 19 vaccine coverage is 
essential if an ongoing cycle of disrup-
tion is to be prevented. Countries that 
have already achieved high coverage 
must show leadership in ensuring 
that doses expected by COVAX are 
prioritised over their own secondary 
needs. Manufacturers must deliver on 
their obligations to the facility, rather 
than focusing on servicing of bilateral 
agreements with individual countries. 
Countries in receipt of COVID- 19 
vaccines must align strategies that 
focus on empowering and protecting 
the most vulnerable members of their 
population, with approaches that will 
promote, rather than disrupt, child and 
adolescent programmes. Finally, profes-
sional bodies, as well as individuals, 
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with a genuine belief in the importance 
of equity must look beyond their own 
shores, and advocate for the importance 
of this unassailable principal, rather 
than on increasing inequity through 
focussing on marginal gains at home.
The unprecedented attention that 
vaccines and vaccine inequity have 
received in the past months, including 
the undoubted achievements as well 
as challenges, should be viewed as a 
springboard to ensure the goal of the 
Immunization Agenda 2030 to leave no 
one behind is ultimately realised.
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